NCT02920554 The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer
| NCT ID | NCT02920554 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Saint Vincent's Hospital, Korea |
| Condition | Gallbladder Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 88 participants |
| Start Date | 2014-07 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 88 participants in total. It began in 2014-07 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The extent of hepatic resection for gallbladder cancer can be done from a wedge resection to 4b/5 bisegmentectomy. This study aims to compare the recurrence rates and survival rates between wedge resection group and bisegmentectomy group. Patients with T2 or T3 gallbladder cancer on preoperative CT exam or patients who were pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy were enrolled. All patients are randomly assigned to wedge resection or bisegmentectomy group. Number of patients in each group is 44. Primary endpoint is recurrence-free-survival rates and overall survival rates.
Eligibility Criteria
Inclusion Criteria: * Patients with T2 or T3 gallbladder cancer on preoperative CT exam * Patients who are pathologically diagnosed as T2 or T3 gallbladder cancer after initial simple cholecystectomy Exclusion Criteria: * Peritoneal seeding or distant metastasis * Impossible to resect the cancer radically * Pathologically diagnosed to other malignancy such as adenosquamous carcinoma, sarcoma, etc. * R1 or R2 resection were pathologically diagnosed.
Contact & Investigator
Dong Do You, MD, PhD
STUDY DIRECTOR
the Catholic Universityof Korea St. Vincent's Hospital
Frequently Asked Questions
Who can join the NCT02920554 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 80 Years, studying Gallbladder Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02920554 currently recruiting?
Yes, NCT02920554 is actively recruiting participants. Contact the research team at tzanggu@catholic.ac.kr for enrollment information.
Where is the NCT02920554 trial being conducted?
This trial is being conducted at Suwon, South Korea.
Who is sponsoring the NCT02920554 clinical trial?
NCT02920554 is sponsored by Saint Vincent's Hospital, Korea. The principal investigator is Dong Do You, MD, PhD at the Catholic Universityof Korea St. Vincent's Hospital. The trial plans to enroll 88 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.